Publikationen in Zusammenarbeit mit Forschern von Universidad Miguel Hernández de Elche (11)

2024

  1. A genome-wide association analysis reveals new pathogenic pathways in gout*

    Nature Genetics

2023

  1. Association of Gout Polygenic Risk Score With Age at Disease Onset and Tophaceous Disease in European and Polynesian Men With Gout

    Arthritis and Rheumatology, Vol. 75, Núm. 5, pp. 816-825

  2. The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease

    Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713

  3. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257

2022

  1. Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland

    Annals of the Rheumatic Diseases

  2. Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction

    Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658

  3. Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases

    Joint Bone Spine, Vol. 89, Núm. 1

  4. Prévalence de la goutte dans la population générale en Espagne : une estimation du taux de cas non diagnostiqués

    Revue du Rhumatisme (Edition Francaise), Vol. 89, Núm. 4, pp. 389-395

2019

  1. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600

2018

  1. Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice

    Rheumatology and Therapy, Vol. 5, Núm. 1, pp. 243-253

2014

  1. Improving cardiovascular and renal outcomes in gout: What should we target?

    Nature Reviews Rheumatology, Vol. 10, Núm. 11, pp. 654-661